ATP-Triggered NBD Immune Agonists for Localized Tumor Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies face limitations such as toxicity, limited efficacy due to low TAA density, on-target/off-tumor toxicity, and safety concerns with stoichiometric enhancements, necessitating a more targeted and safer approach for tumor-specific immune stimulation.
Innovation Solution
Development of nucleotide binding domain (NBD)-containing constructs that assemble into dimers or higher order complexes in the tumor microenvironment (TME) using ATP as a trigger, enhancing immune cell stimulation and payload delivery, while minimizing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If systemic delivery of immune agonists is used, then broad distribution is achieved, but severe toxicity occurs
Solution Approach 1:
The patent applies local quality by designing immune agonists that are activated specifically in the tumor microenvironment through pH-sensitive or enzyme-sensitive linkers. The therapeutic agent remains inactive in systemic circulation (pH 7.4) and is only activated in the acidic tumor microenvironment (pH 6.5-7.0), providing local therapeutic action while minimizing systemic toxicity
Solution Approach 2:
The patent uses tumor-specific enzymes (such as matrix metalloproteinases) or acidic pH as intermediaries to trigger activation of the prodrug. These intermediaries are abundant in the tumor microenvironment but absent in normal tissues, enabling selective activation and reducing off-target effects
2Measurement precision
If TAA-targeted immune agonists are used, then tumor specificity is improved, but low TAA density results in low efficacy
Solution Approach 1:
The patent combines multiple targeting strategies by linking immune agonists to antibodies against multiple tumor-associated antigens simultaneously. This multi-targeting approach ensures that even if one TAA is expressed at low density, the cumulative effect of binding to multiple TAAs achieves sufficient tumor cell coverage and therapeutic efficacy
Solution Approach 2:
The patent creates composite immunotherapeutic agents that integrate antibody targeting domains with immune agonist domains in a single molecular construct. This composite structure enables both specific tumor targeting and potent immune activation, overcoming the limitation of low TAA density by concentrating multiple functional elements in one molecule
3Power
If stoichiometric enhancement of immune agonists is used, then in vitro potency is improved, but severe toxicity occurs in clinical trials
Solution Approach 1:
The patent employs dynamic control of immune agonist activity through conditional activation mechanisms. The immune agonist is delivered in an inactive prodrug form systemically and only becomes active upon encountering tumor-specific conditions (acidic pH or enzymes), dynamically switching from low systemic activity to high local activity at the tumor site
Solution Approach 2:
The patent utilizes parameter changes in the tumor microenvironment (particularly pH and enzyme presence) to control the activation state of the immune agonist. The chemical structure of the prodrug is designed to undergo conformational changes or cleavage in response to these parameter changes, transforming from an inactive to an active state selectively in the tumor
4Quantity of substance
If intratumoral administration is used, then local concentration is improved, but surgical complexity increases
Solution Approach 1:
The patent designs the immune agonist to be self-activating in response to tumor microenvironment conditions. After systemic administration, the prodrug automatically activates in the tumor without requiring surgical intervention or external triggers, achieving high local concentration through the body's own physiological parameters
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The NBD-containing constructs provide potent, localized immune stimulation and enhanced payload delivery to tumors, reducing systemic side effects and increasing therapeutic index by leveraging universal ATP levels in TMEs.
Implementation Method 1
molecular constructs comprising nucleotide binding domains (NBDs) that enable the use of tumor ATP as a trigger for the conditional (ATP-dependent) assembly of potent cancer therapeutic agents at the tumor
Data Source
AI summary
The present disclosure provides polypeptide constructs that act as agonists of immune cell function when exposed to sufficient levels of ATP to cause their assembly into dimers or higher order complexes (e.g., trimers, tetramers, etc.). The constructs may also be conjugated to one or more therapeutic agent, chemotherapeutic agent, or labeling agent. The complexes of the constructs are capable of stimulating immune cells (e.g., cytotoxic CD8+ T cells and/or NK cells) that function to promote anti-tumor immune responses and delivering the conjugated agents into the tumor microenvironment. The constructs may be employed as anticancer agents/therapeutics for the treatment of solid tumors that have elevated levels of ATP.